Academia.eduAcademia.edu

Outline

Title
Abstract
References
All Topics
Biology
Immunology

Emerging pathogens in transfusion medicine

Profile image of Roger DoddRoger Dodd

2010, Clinics in laboratory medicine

https://doi.org/10.1016/J.CLL.2010.02.007
visibility

…

description

12 pages

link

1 file

Abstract

Although the risk of infection with hepatitis and human immunodeficiency viruses from blood transfusions has been reduced to negligible levels, emerging infections continue to offer threats. Such threats occur with any infection that has an asymptomatic, blood-borne phase. In the past, it was thought that any emerging transfusion-transmitted disease would have epidemiologic properties similar to those of AIDS or viral hepatitis. Over the past 20 years, however, greatest concern has arisen from variant Creutzfeldt-Jakob disease, West Nile virus, and Babesia. These and other emerging infections are discussed in the context of blood safety.

Related papers

Transfusion-transmitted infectious diseases
Fernando Proietti

Biologicals, 2009

A spectrum of blood-borne infectious agents is transmitted through transfusion of infected blood donated by apparently healthy and asymptomatic blood donors. The diversity of infectious agents includes hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency viruses (HIV-1/2), human T-cell lymphotropic viruses (HTLV-I/II), Cytomegalovirus (CMV), Parvovirus B19, West Nile Virus (WNV), Dengue virus, trypanosomiasis, malaria, and variant CJD. Several strategies are implemented to reduce the risk of transmitting these infectious agents by donor exclusion for clinical history of risk factors, screening for the serological markers of infections, and nucleic acid testing (NAT) by viral gene amplification for direct and sensitive detection of the known infectious agents. Consequently, transfusions are safer now than ever before and we have learnt how to mitigate risks of emerging infectious diseases such as West Nile, Chikungunya, and Dengue viruses.

View PDFchevron_right
Transfusion-transmitted infections
Florian Bihl, Roger Dodd

Journal of Translational Medicine, 2007

Although the risk of transfusion-transmitted infections today is lower than ever, the supply of safe blood products remains subject to contamination with known and yet to be identified human pathogens. Only continuous improvement and implementation of donor selection, sensitive screening tests and effective inactivation procedures can ensure the elimination, or at least reduction, of the risk of acquiring transfusion transmitted infections. In addition, ongoing education and up-to-date information regarding infectious agents that are potentially transmitted via blood components is necessary to promote the reporting of adverse events, an important component of transfusion transmitted disease surveillance. Thus, the collaboration of all parties involved in transfusion medicine, including national haemovigilance systems, is crucial for protecting a secure blood product supply from known and emerging blood-borne pathogens.

View PDFchevron_right
NEW EMERGING VIRUSES AND TRANSFUSION SAFETY
IJAR Indexing

International Journal of Advanced Research (IJAR), 2025

Blood transfusion is one of the most sensitive and delicate activities in a health system, due to the human nature of the products used. Viral safety remains a major concern. SARS-CoV2, Ebola virus, hepatitis E, Human T-lymphotrophic viruses type I and II (HTLV), Monkeypox (Mpox), Human herpesvirus (HHV-8), Erythrovirus and Arboviruses. In addition to being infections transmitted by vectors (mainly mosquitoes), they have the common denominator of being responsible for epidermal explosions when the conditions for entomological expansion are met. These infections have the particularity of being responsible for a viremia that is generally short-lived (less than aweek on average), but which precedes the appearance of clinical signs by 1 to 2 days, a period during which a subject is infectious and can pass the filter of the pre-donation interview. The transfusion safety associated with SARS-CoV2, Ebola virus, Hepatitis E, HTLV, Mpox, HHV-8, Erythrovirus and Arboviruses were only recognized. The dawn of the 21st century for the oldest and much more recently for the others. This paradox is due to the fact that most of these viral infections have been known and described since the 1950s, mainly in tropical countries with a low socio-economic level where the transfusion risk has long been neglected. It was not until these infections became established in territories applying modern haemovigilance rules that transfusion safety was formally identified. In this work, we describe the different experiences of several countries that have experienced major obstacles when performing blood transfusions, due to epidemics of SARS-CoV2, Ebola virus, Hepatitis E, HTLV, Mpox, HHV-8, Erythrovirus and Arboviruses.

View PDFchevron_right
The potential threat to blood transfusion safety of emerging infectious disease agents
Susan Stramer

Clinical advances in hematology & oncology : H&O, 2015

H&O How safe is the US blood supply at this time? SS The blood supply with respect to known infectious disease agents-such as HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV)-is very safe because of donor selection, donor screening, and blood donation testing. The per unit risk of contamination with HIV is approximately 1 in 1,000,000 units, which is also true for both HBV and HCV (see the table). People who receive multiple units are therefore at higher risk. The risk of receiving a bacteria-contaminated unit that causes a septic transfusion event is higher-approximately 1 in 109,000. Although we use strategies to mitigate the risk of contamination, most contaminating bacteria are common because they are present on the donor's skin. H&O Are there agents that we currently do not test for that pose a potential risk?

View PDFchevron_right
Prevention of transfusion-transmitted infections
Michael P Busch

Blood, 2019

Since the 1970s, introduction of serological assays targeting virus-specific antibodies and antigens has been effective in identifying blood donations infected with the classic transfusion-transmitted infectious agents (TTIs; hepatitis B virus [HBV], HIV, human T-cell lymphotropic virus types I and II, hepatitis C virus [HCV]). Subsequently, progressive implementation of nucleic acid–amplification technology (NAT) screening for HIV, HCV, and HBV has reduced the residual risk of infectious-window-period donations, such that per unit risks are <1 in 1 000 000 in the United States, other high-income countries, and in high-incidence regions performing NAT. NAT screening has emerged as the preferred option for detection of newer TTIs including West Nile virus, Zika virus (ZIKV), and Babesia microti. Although there is continual need to monitor current risks due to established TTI, ongoing challenges in blood safety relate primarily to surveillance for emerging agents coupled with devel...

View PDFchevron_right
Emerging transfusion transmitted infections: species barriers and the risks for transfusion medicine
Roger Dodd

ISBT Science Series, 2008

View PDFchevron_right
Transfusion‐transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis
Michael P Busch

ABBREVIATIONS: ARC = American Red Cross; FT = first-time (donor); IR-WP = incidence rate-window period; MP = minipool; NANBH = non-A, non-B hepatitis; PTH = posttransfusion hepatitis; RPT = repeat; TA = transfusion-associated; TSS = Transfusion Safety Study; TTVI(s) = transfusion-transmitted viral infection(s); TTVS = Transfusion-Transmitted Viruses Study; WNV = West Nile virus; WP(s) = window period(s).

View PDFchevron_right
Assessing Emerging Infectious Threats to Blood Safety for the Blood Disorders Community
Sean Trimble

American Journal of Preventive Medicine, 2010

Technologic advances in diagnostic testing, vaccinations, pathogen inactivation, and vigilant donor screening have greatly reduced the risk of transmitting pathogens through blood transfusion. Nevertheless, transfusion-related infections and fatalities continue to be reported, and emerging pathogens continue to become an increasing threat to the blood supply. This threat is even greater to patients with blood disorders, who are heavily transfused and rely on safe blood products. This article describes some of the emerging and re-emerging transfusion-transmitted pathogens that have increased in incidence in the U.S. in recent years. Peer-reviewed articles and agency websites were the sources of information. The article focuses on the treatment of hereditary blood disorders including hemophilia and thalassemia, and hereditary bone marrow failure. A coordinated approach to addressing blood safety and continued development of sensitive diagnostic testing are necessary to reduce risk in an increasingly globalized society.

View PDFchevron_right
The risk of contracting an infectious disease from blood transfusion
L. Nelli

Transplantation Proceedings, 2004

In the general population, the likelihood of an individual receiving a transfusion has been calculated to be about 0.89% per year, increasing dramatically with age. Massive intraoperative hemorrhage from trauma, cardiopulmonary bypass, and orthotopic liver transplantation need substantial replacement therapy. In renal transplantation, blood transfusion is a debated induction tool for specific allograft tolerance, since it causes a nonspecific down-regulation of immune function. In transplantations, in humoral immune deficiencies, in hematological disorders, and in HIV infection, the intravenous immunoglobulin prophylaxis may alter the monocyte/macrophage system host immunity and immune surveillance against infection, tissue or cell damage, and malignancy. Some persons, like Jehovah's Witnesses, object to transfusion of blood products, posing ethical and practical issues concerning treatment of blood disorders, transplantation, and trauma. In this review we examined the actual risk of contracting an infectious disease from an allogeneic blood transfusion to contribute to an uneasy decision-making process. We have found that the procedure is presently considerably safe.

View PDFchevron_right
Current risks of transfusion-transmitted agents: a review
Susan Stramer

Archives of pathology & laboratory medicine, 2007

Infectious disease testing has dramatically improved the safety of blood for transfusion in the United States, especially since the introduction in 1999 of nucleic acid amplification testing. In 2004, methods (primarily culturing) for detecting bacteria in platelets were also added. To provide current risk estimates for the likelihood of viral transmission by test-negative blood components and to illustrate the safety improvements since the introduction of bacterial testing of platelets. Published literature from 1999 through 2006 and unpublished American Red Cross data sources. The risk of human immunodeficiency virus and hepatitis C virus transmission through blood transfusion since the introduction of nucleic acid amplification testing is approximately 1 in 2 million. Hepatitis B virus risk, for which nucleic acid amplification testing is not performed routinely, remains at 1 in 200,000 to 500,000 using a combination of anti-hepatitis B core and hepatitis B surface antigen testin...

View PDFchevron_right

References (54)

  1. Weiss RA, McMichael AJ. Social and environmental risk factors in the emergence of infectious diseases. Nat Med 2004;10:S70-6.
  2. Wolfe ND, Dunavan CP, Diamond J. Origins of major human infectious diseases. Nature 2007;447:279-83.
  3. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302: 276-8.
  4. Vijayanand P, Wilkins E, Woodhead M. Severe acute respiratory syndrome (SARS): a review. Clin Med 2004;4:152-60.
  5. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion. 2009;49(Suppl 2):1S-29S.
  6. Dodd
  7. Peterman TA, Jaffe HW, Feorino PM, et al. Transfusion-associated acquired immunodeficiency syndrome in the United States. JAMA 1985;254:2913-7.
  8. Barre-Sinoussi F, Chermann J-C, Rey F, et al. Isolation of a T-lymphotropic retro- virus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
  9. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984;224:500-3.
  10. Peterman TA, Lui K-J, Lawrence DN, et al. Estimating the risks of transfusion- associated acquired immune deficiency syndrome and human immunodefi- ciency virus infection. Transfusion 1987;27:371-4.
  11. Busch MP, Young MJ, Samson SM, et al. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. Transfusion 1991;31:4-11.
  12. Schorr JB, Berkowitz A, Cumming PD, et al. Prevalence of HTLV-III antibodies in American blood donors. N Engl J Med 1985;313:384-5.
  13. Apetrei C, Loussert-Ajaka I, Descamps D, et al. Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions. AIDS 1996;10:F57-60.
  14. Schable C, Zekeng L, Pau C-P, et al. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet 1994;344:1333-4.
  15. Hewitt PE, Llewelyn CA, Mackenzie J, et al. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006;91:221-30.
  16. Zou S, Fang CT, Schonberger LB. Transfusion transmission of human prion diseases. Transfus Med Rev 2008;22:58-69.
  17. Houston F, McCutcheon S, Goldmann W, et al. Prion diseases are efficiently trans- mitted by blood transfusion in sheep. Blood 2008;112:4739-45.
  18. Sowemimo-Coker SO, Pesci S, Andrade F, et al. Pall leukotrap affinity prion- reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates. Vox Sang 2006;90:265-75.
  19. Gregori L, Gurgel PV, Lathrop JT, et al. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006;368:2226-30.
  20. Petersen LR, Hayes EB. Westward ho?-The spread of West Nile virus. N Engl J Med 2004;351:2257-9.
  21. Biggerstaff BJ, Petersen LR. Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City. Trans- fusion 2002;42:1019-26.
  22. Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003; 349:1236-45.
  23. Dodd RY. Emerging infections, transfusion safety, and epidemiology. N Engl J Med 2003;349:1205-6.
  24. Schmun ˜is GA. Trypanosoma cruzi, the etiologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries. Transfusion 1991;31: 547-57.
  25. Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. Clin Micro- biol Rev 2005;18:12-29.
  26. Leiby DA, Read EJ, Lenes BA, et al. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors. J Infect Dis 1997;176: 1047-52.
  27. Bern C, Montgomery SP, Katz L, et al. Chagas disease and the US blood supply. Curr Opin Infect Dis 2008;21:476-82.
  28. Leiby DA. Babesiosis and blood transfusion: flying under the radar. Vox Sang 2006;90:157-65.
  29. Gubernot DM, Lucey CT, Lee KC, et al. Babesia infection through blood transfu- sions: reports received by the US Food and Drug Administration, 1997-2007. Clin Infect Dis 2009;48:25-30.
  30. Tonnetti L, Eder AF, Dy B, et al. Transfusion-transmitted Babesia microti identified through hemovigilance. Transfusion 2009;49:2557-63.
  31. Chuang VW, Wong TY, Leung YH, et al. Review of dengue fever cases in Hong Kong during 1998 to 2005. Hong Kong Med J 2008;14:170-7.
  32. Tambyah PA, Koay ES, Poon ML, et al. Dengue hemorrhagic fever transmitted by blood transfusion. N Engl J Med 2008;359:1526-7.
  33. Linnen JM, Vinelli E, Sabino EC, et al. Dengue viremia in blood donors from Honduras, Brazil, and Australia. Transfusion 2008;48:1355-62.
  34. Mohammed H, Linnen JM, Munoz-Jordan JL, et al. Dengue virus in blood dona- tions, Puerto Rico, 2005. Transfusion 2008;48:1348-54.
  35. Kumarasamy V, Wahab AH, Chua SK, et al. Evaluation of a commercial dengue NS1 antigen-capture ELISA for laboratory diagnosis of acute dengue virus infec- tion. J Virol Methods 2007;140:75-9.
  36. Charrel RN, de L X, Raoult D. Chikungunya outbreaks-the globalization of vectorborne diseases. N Engl J Med 2007;356:769-71.
  37. Tsetsarkin KA, Vanlandingham DL, McGee CE, et al. A single mutation in chikun- gunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007; 3:e201.
  38. Brouard C, Bernillon P, Quatresous I, et al. Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion 2008;48:1333-41.
  39. Rezza G, Nicoletti L, Angelini R, et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 2007;370:1840-6.
  40. Lanciotti RS, Kosoy OL, Laven JJ, et al. Chikungunya virus in US travelers return- ing from India, 2006. Emerg Infect Dis 2007;13:764-7.
  41. Dorsey K, Zou S, Schonberger LB, et al. Lack of evidence of transfusion transmis- sion of Creutzfeldt-Jakob disease in a US surveillance study. Transfusion 2009; 49:977-84.
  42. Belay ED, Maddox RA, Williams ES, et al. Chronic wasting disease and potential transmission to humans. Emerg Infect Dis 2004;10:977-84.
  43. Belay ED, Gambetti P, Schonberger LB, et al. Creutzfeldt-Jakob disease in unusually young patients who consumed venison. Arch Neurol 2001;58:1673-8.
  44. Jones-Engel L, Engel GA, Schillaci MA, et al. Primate-to-human retroviral trans- mission in Asia. Emerg Infect Dis 2005;11:1028-35.
  45. Switzer WM, Bhullar V, Shanmugam V, et al. Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates. J Virol 2004;78: 2780-9.
  46. Brooks JI, Merks HW, Fournier J, et al. Characterization of blood-borne transmis- sion of simian foamy virus. Transfusion 2007;47:162-70.
  47. Khan AS, Kumar D. Simian foamy virus infection by whole-blood transfer in rhe- sus macaques: potential for transfusion transmission in humans. Transfusion 2006;46:1352-9.
  48. Boneva RS, Grindon AJ, Orton SL, et al. Simian foamy virus infection in a blood donor. Transfusion 2002;42:886-91.
  49. Dodd
  50. Winkler IG, Flu ¨gel RM, Asikainen K, et al. Antibody to human foamy virus not de- tected in individuals treated with blood products or in blood donors. Vox Sang 2000;79:118-9.
  51. O'Brien SF, Yi QL, Fearon MA, et al. A predonation screening question for occu- pational exposure to simian foamy virus: a preliminary donor survey in Canada. Transfusion 2007;47:949-50.
  52. Lombardi VC, Ruscetti FW, Das GJ, et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009; 326:585-9.
  53. Prowse C, Robinson AE. Pathogen inactivation of labile blood components. Transfus Med 2001;11:147.
  54. Webert KE, Cserti CM, Hannon J, et al. Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008;22:1-34.

Related papers

Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections
Susan Stramer

ISBT Science Series, 2014

to Transfusion that reviewed emerging infectious disease (EID) agents that pose a real or theoretical threat to transfusion safety, but for which an existing effective intervention is lacking. The necessary attributes for transfusion transmission were outlined including: presence of the agent in blood during the donor's asymptomatic phase, the agent's survival/persistence in blood during processing/storage, and lastly that the agent must be recognized as responsible for a clinically apparent outcome in at least a proportion of recipients who become infected. Without these attributes, agents are not considered as a transfusion-transmission threat and were excluded. Sixty-eight such agents were identified with enough evidence/likelihood of transfusion transmission (e.g., blood phase) and potential for clinical disease to warrant further consideration. In the Supplement, Fact Sheets (FS) were published providing information on: agent classification; disease agent's importance; clinical syndromes/diseases caused; transmission modes (including vectors/reservoirs); likelihood of transfusion transmission, and if proven to be transfusion-transmitted, information on known cases; the feasibility/predicted success of interventions for donor screening (questioning) and tests available for diagnostics/ adapted for donor screening; and finally, the efficacy, if known, of inactivation methods for plasma-derived products. The Supplement included a separate section on pathogen reduction using published data. Agents were prioritized relative to their scientific/epidemiologic threat and their perceived threat to the community including concerns expressed by the regulators of blood. Agents given the highest priority due to a known transfusiontransmission threat and severe/fatal disease in recipients were the vCJD prion, dengue viruses and the obligate red-cell parasite that causes babesiosis (B. microti and related Babesia). Although the focus of the Supplement was towards the United States and Canada, many of the agents (and the process) are applicable worldwide. Next steps Since the publication of the Supplement, six new FSs (yellow fever viruses-including vaccine breakthrough infections, miscellaneous arboviruses, XMRV, human parvoviruses/bocaviruses other than B19, and most recently the Middle East respiratory syndrome coronavirus, MERS-CoV) were added and 14 existing FSs updated (Anaplasma, Babesia, Bartonella, Erhlichia, chronic wasting

View PDFchevron_right
Current risk for transfusion transmitted infections
Roger Dodd

Current opinion in hematology, 2007

Blood safety is a topic of continuing concern, and much effort is expended on measures to decrease the risk for transmission of infectious agents via transfusion. At the same time, emerging infections may threaten this safety. A periodic review of risk is therefore appropriate. The risk for major transfusion transmissible infections continues to decline as a result of continually strengthening interventions and because of more general improvements in public health. More attention is being paid to emerging infections, and recently donor testing has been implemented for West Nile virus and Trypanosoma cruzi. Within the period covered by this review, the transmission of variant Creutzfeldt-Jakob disease by transfusion has been confirmed. Our understanding of other agents is improving. The estimated risk for transfusion transmitted hepatitis viruses and retroviruses is now vanishingly small, but clinicians should be alert to the possibility of infection with emerging infectious agents, ...

View PDFchevron_right
Current and Emerging Infectious Risks of Blood Transfusions
Michael P Busch

JAMA, 2003

View PDFchevron_right
Emerging infections in transfusion medicine
Michael P Busch

Clinics in Laboratory Medicine, 2004

View PDFchevron_right
Emerging infectious disease agents and their potential threat to transfusion safety
Roger Dodd

Transfusion, 2009

BACKGROUND: Emerging infections have been identified as a continuing threat to human health. Many such infections are known to be transmissible by blood transfusion, while others have properties indicating this potential. There has been no comprehensive review of such infectious agents and their threat to transfusion recipient safety to date.STUDY DESIGN AND METHODS: The members of AABB's Transfusion Transmitted Diseases Committee reviewed a large number of information sources in order to identify infectious agents with actual or potential risk of transfusion transmission now or in the future in the US or Canada; with few exceptions, these agents do not have available interventions to reduce the risk of such transmission. Using a group discussion and writing process, key characteristics of each agent were identified, researched, recorded and documented in standardized format. A group process was used to prioritize each agent on the basis of scientific/epidemiologic data and a subjective assessment of public perception and/or concern expressed by regulatory agencies.RESULTS: Sixty-eight infectious agents were identified and are described in detail in a single Supplement to TRANSFUSION. Key information will also be provided in web-based form and updated as necessary. The highest priorities were assigned to Babesia species, Dengue virus, and vCJD.CONCLUSION: The information is expected to support the needs of clinicians and transfusion medicine experts in the recognition and management of emerging infections among blood donors and blood recipients.

View PDFchevron_right

Related topics

  • Immunology
  • Virology
  • Medicine
  • Transfusion medicine
  • Chagas disease
  • Blood Borne Pathogens
    • 580 California St., Suite 400
    San Francisco, CA, 94104
    © 2025 Academia. All rights reserved